NCT06557356

A Study of LY3532226 in Participants With Obesity

A Dose-Escalation Phase 1, Investigator- and Participant-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3532226 in Participants With Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 132 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it following weekly or monthly administration. Part A of the study will last approximately 16 weeks, excluding screening period. Part B of the study will last approximately 20 weeks, excluding the screening period. Part C of the study will last approximately 8 weeks, excluding the screening period.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	LY3532226	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2024-08-16
• Primary completion: 2025-12-12
• Completion: 2025-12-12
• First posted: 2024-08-16
• Last updated: 2026-01-20

Locations

4 sites across 2 countries: United States, Singapore

Regulatory

• FDA-regulated drug study